Provided that the combination therapy is well tolerated, these data will also inform the planned phase II randomized clinical trial evaluating the efficacy of combined CDK4/6i and RT in women with multiple lymph node–positive (LN+) ER+ breast cancer (>3 LN). The gene discussed is CDK4; the disease is breast cancer.